Cryoport Inc. and Medipal Holdings Corporation have announced a multi-year strategic business alliance agreement to create an integrated regenerative medicine supply chain solution in Japan.
 
Cryoport and Medipal will partner to provide integrated, end-to-end distribution solutions for specialty cell and gene therapies that demand stringent temperature control, track and trace systems and global distribution. To meet demand from the increasing number of cell and gene therapies currently in development and expected to launch in coming years, this alliance will combine both companies’ strengths to realize reliable and seamless distribution services for biopharmaceutical companies in Japan and the Asia-Pacific region/worldwide.
 
Shuichi Watanabe, representative director, president and CEO commented, “This alliance with Cryoport will enable our two companies to seamlessly provide an integrated, high-quality logistics service in the Japanese market, as well as overseas, complementing each other’s strengths. We also believe that this alliance will accelerate our progress to satisfy unmet medical needs, both domestically and internationally, and it will help patients awaiting new treatment options, as well as the treating physicians.”
 
Cryoport supports over 465 clinical trials globally, and multiple cell and gene therapies in commercial distribution. Its suite of temperature-controlled solutions for the life sciences industry enables users to monitor their shipments and track the conditions, location, and courier handling of their biological commodities in transit around the clock. And should a problem occur that warrants intervention, Cryoport can deploy intervention capability to mitigate the situation.
 
Medipal provides efficient, reliable, and timely distribution solutions for specialty products in the healthcare industry across a broad range of temperatures, with strict temperature control and traceability. With its logistics, including the original SDDU (Specialty Drug Distribution Unit: a long-life shipping unit using liquid nitrogen in liquid phase for ultra-low temperature logistics), Medipal has positioned itself as a unique leader in cell and gene therapy product logistics in Japan. The goal of the partnership is to provide fully integrated solutions that reduce risk and improve certainty for the companies and global clients.